Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane F Apperley

Showing results (91-100 of 195) with videos related to

Pageof 20
Sort By:
Cell Reports|February 16, 2017
Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell PrecursorsBryant Boulianne, Mark E Robinson, Philippa C May, et al.
American Journal of Clinical Pathology|March 13, 2002
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic responseRobert P Hasserjian, Federica Boecklin, Sally Parker, et al.
British Journal of Haematology|December 19, 2021
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitorsSimone Claudiani, Jane F Apperley, Eleanor L Parker, et al.
Leukemia Research|November 3, 2009
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemiaHugues de Lavallade, Pascal Finetti, Nadine Carbuccia, et al.
British Journal of Haematology|December 28, 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemiaSimone Claudiani, Jane F Apperley, Richard Szydlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisHugues de Lavallade, Jane F Apperley, Jamshid S Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progressionJamshid S Khorashad, Hugues de Lavallade, Jane F Apperley, et al.
Hematological Oncology|July 17, 2010
LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centreJiří Pavlů, Holger W Auner, Sarah Ellis, et al.
Leukemia & Lymphoma|February 8, 2013
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantationHolger W Auner, Richard Szydlo, Alero Rone, et al.
British Journal of Haematology|March 12, 2008
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesisHugues de Lavallade, Sinthiya Punnialingam, Dragana Milojkovic, et al.
Pageof 20

Showing results (91-100 of 195) with videos related to

Sort By:
Pageof 20
Cell Reports|February 16, 2017
Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell PrecursorsBryant Boulianne, Mark E Robinson, Philippa C May, et al.
American Journal of Clinical Pathology|March 13, 2002
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic responseRobert P Hasserjian, Federica Boecklin, Sally Parker, et al.
British Journal of Haematology|December 19, 2021
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitorsSimone Claudiani, Jane F Apperley, Eleanor L Parker, et al.
Leukemia Research|November 3, 2009
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemiaHugues de Lavallade, Pascal Finetti, Nadine Carbuccia, et al.
British Journal of Haematology|December 28, 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemiaSimone Claudiani, Jane F Apperley, Richard Szydlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisHugues de Lavallade, Jane F Apperley, Jamshid S Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progressionJamshid S Khorashad, Hugues de Lavallade, Jane F Apperley, et al.
Hematological Oncology|July 17, 2010
LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centreJiří Pavlů, Holger W Auner, Sarah Ellis, et al.
Leukemia & Lymphoma|February 8, 2013
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantationHolger W Auner, Richard Szydlo, Alero Rone, et al.
British Journal of Haematology|March 12, 2008
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesisHugues de Lavallade, Sinthiya Punnialingam, Dragana Milojkovic, et al.
Pageof 20